Feasibility of INSPIRE Technology to Enhance CRISPR Mediated Genome Editors In Vivo
Award amount
$251,914Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GRADIENT MEDICAL, INC.
- Proposal award date
- 2021-09-01
- Contract end date
- 2022-08-31
- UEI
- HPZ7FS9MF8J1
- Solicitation number
- PAR20-098
- Topic code
- 400
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Commercialization of Algorithmic Non-thermal Ablation Technology for the Treatment of Inoperable Tumors
- Feasibility of a Multi-Phase Algorithmic Non-Thermal Ablation Technology for the Treatment of Inoperable Tumors
- SBIR Phase I: Pulsed Electric Field Mediated Intradermal Vaccine Delivery (COVID-19)
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes
- Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials
- Dynamical Diffraction Analysis for 3D Electron Crystallography
- Synthetic biology approaches for bio-orthogonal labeling of circular RNAs
- Break Wave lithotripsy to fragment large kidney stones
Research funding history
4 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $1,917,393. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation